Market Closed -
Nyse
04:00:00 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.925
USD
|
-4.64%
|
|
-9.31%
|
-15.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
133.3
|
264
|
413
|
198.9
|
190.7
|
183.2
|
-
|
-
|
Enterprise Value (EV)
1 |
133.3
|
264
|
413
|
198.9
|
190.7
|
183.2
|
183.2
|
183.2
|
P/E ratio
|
-11.1
x
|
-12.6
x
|
-9.42
x
|
-7.8
x
|
-9.08
x
|
-7.46
x
|
-5.64
x
|
-6.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.9
x
|
145
x
|
95.1
x
|
13.5
x
|
21.3
x
|
15
x
|
31.2
x
|
8.02
x
|
EV / Revenue
|
37.9
x
|
145
x
|
95.1
x
|
13.5
x
|
21.3
x
|
15
x
|
31.2
x
|
8.02
x
|
EV / EBITDA
|
-3.73
x
|
-10.8
x
|
-8.54
x
|
-9.13
x
|
-7.93
x
|
-7.02
x
|
-7.59
x
|
-16.5
x
|
EV / FCF
|
-
|
-
|
-
|
308
x
|
-6.52
x
|
-35.2
x
|
-4.64
x
|
-5.06
x
|
FCF Yield
|
-
|
-
|
-
|
0.32%
|
-15.3%
|
-2.84%
|
-21.5%
|
-19.8%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
149,794
|
149,991
|
168,558
|
169,976
|
174,987
|
188,824
|
-
|
-
|
Reference price
2 |
0.8900
|
1.760
|
2.450
|
1.170
|
1.090
|
0.9700
|
0.9700
|
0.9700
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.515
|
1.826
|
4.341
|
14.7
|
8.945
|
12.22
|
5.869
|
22.83
|
EBITDA
1 |
-35.75
|
-24.34
|
-48.34
|
-21.79
|
-24.04
|
-26.1
|
-24.14
|
-11.08
|
EBIT
1 |
-38.88
|
-26.45
|
-49.21
|
-22.52
|
-24.73
|
-30
|
-34.86
|
-26.36
|
Operating Margin
|
-1,106%
|
-1,448.36%
|
-1,133.63%
|
-153.17%
|
-276.5%
|
-245.45%
|
-593.94%
|
-115.48%
|
Earnings before Tax (EBT)
1 |
-19.23
|
-21.92
|
-43.27
|
-25.81
|
-23.28
|
-28.62
|
-32.25
|
-30.05
|
Net income
1 |
-11.71
|
-20.65
|
-43.02
|
-26.27
|
-21.49
|
-29.64
|
-32.25
|
-30.05
|
Net margin
|
-333.12%
|
-1,130.83%
|
-990.99%
|
-178.69%
|
-240.2%
|
-242.55%
|
-549.47%
|
-131.64%
|
EPS
2 |
-0.0800
|
-0.1400
|
-0.2600
|
-0.1500
|
-0.1200
|
-0.1300
|
-0.1720
|
-0.1450
|
Free Cash Flow
1 |
-
|
-
|
-
|
0.646
|
-29.24
|
-5.2
|
-39.45
|
-36.2
|
FCF margin
|
-
|
-
|
-
|
4.39%
|
-326.89%
|
-42.55%
|
-672.14%
|
-158.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.9
|
1.168
|
5.237
|
4.553
|
2.998
|
1.915
|
2.386
|
3.225
|
1.246
|
2.118
|
1.444
|
0.786
|
1.304
|
14.4
|
0.4323
|
0.4323
|
EBITDA
1 |
-11.89
|
-28.05
|
-6.214
|
-4.055
|
-5.058
|
-6.466
|
-6.471
|
-4.854
|
-6.529
|
-6.187
|
-6.486
|
-7.495
|
-6.155
|
-5.9
|
-7.38
|
-7.42
|
EBIT
1 |
-
|
-28.24
|
-6.396
|
-4.234
|
-5.251
|
-6.639
|
-6.642
|
-5.024
|
-6.705
|
-6.362
|
-6.661
|
-8.181
|
-8.776
|
-0.4112
|
-10.02
|
-10.07
|
Operating Margin
|
-
|
-2,417.64%
|
-122.13%
|
-92.99%
|
-175.15%
|
-346.68%
|
-278.37%
|
-155.78%
|
-538.12%
|
-300.38%
|
-461.29%
|
-1,040.81%
|
-672.82%
|
-2.86%
|
-2,318.83%
|
-2,329.24%
|
Earnings before Tax (EBT)
1 |
-14.96
|
-28.01
|
-7.093
|
-6.782
|
-5.575
|
-6.362
|
-6.207
|
-5.203
|
-7.158
|
-4.714
|
-6.558
|
-7.985
|
-7.901
|
-1.069
|
-10.02
|
-10.07
|
Net income
1 |
-14.92
|
-28.99
|
-7.087
|
-6.763
|
-6.069
|
-6.354
|
-4.372
|
-5.229
|
-7.11
|
-4.775
|
-6.542
|
-7.989
|
-7.891
|
-1.081
|
-10.02
|
-10.08
|
Net margin
|
-1,657.78%
|
-2,482.02%
|
-135.33%
|
-148.54%
|
-202.43%
|
-331.8%
|
-183.24%
|
-162.14%
|
-570.63%
|
-225.45%
|
-453.05%
|
-1,016.36%
|
-604.95%
|
-7.51%
|
-2,317.33%
|
-2,331.78%
|
EPS
2 |
-0.1000
|
-0.1700
|
-0.0400
|
-0.0400
|
-0.0400
|
-0.0300
|
-0.0300
|
-0.0300
|
-0.0400
|
-0.0200
|
-0.0400
|
-0.0450
|
-0.0450
|
0.0133
|
-0.0500
|
-0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
3/10/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/9/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/7/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
0.65
|
-29.2
|
-5.2
|
-39.5
|
-36.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.44
|
-
|
-
|
0.41
|
0.67
|
-
|
-
|
0.5
|
Capex / Sales
|
12.52%
|
-
|
-
|
2.81%
|
7.53%
|
-
|
-
|
2.19%
|
Announcement Date
|
3/12/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
0.97
USD Average target price
5.2
USD Spread / Average Target +436.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.14% | 183M | | +49.41% | 57.87B | | +41.65% | 40.25B | | -6.72% | 39.94B | | -5.96% | 28.54B | | +12.99% | 26.4B | | -19.82% | 19.33B | | +32.35% | 12.4B | | -0.08% | 12.23B | | +25.18% | 12.2B |
Other Biotechnology & Medical Research
|